Loading...
XHKG
1177
Market cap9.16bUSD
Apr 03, Last price  
3.89HKD
1D
-1.52%
1Q
27.12%
Jan 2017
60.08%
Name

Sino Biopharmaceutical Ltd

Chart & Performance

D1W1MN
No data to show
P/E
28.59
P/S
2.54
EPS
0.13
Div Yield, %
1.54%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
4.63%
Revenues
26.20b
-8.97%
1,119,075,526787,023,641736,635,8861,090,687,3752,009,498,7232,855,868,5013,482,314,0544,679,808,3936,704,567,4617,736,862,5109,898,228,01612,184,063,75914,170,151,72014,819,302,00020,888,584,00024,234,030,00023,647,224,00026,861,356,00028,780,412,00026,199,409,000
Net income
2.33b
-53.39%
179,345,8351,720,255,079141,553,227210,173,021262,051,334349,504,916483,123,793374,557,900717,232,356810,134,5051,210,019,7621,489,440,6601,713,153,9232,170,951,0009,046,347,0004,694,374,0004,340,667,00014,608,412,0005,002,618,0002,331,939,000
CFO
6.07b
-3.18%
242,135,043274,525,023112,559,141236,525,096365,890,986604,597,492428,388,791885,935,9691,294,881,2361,231,462,0531,839,326,3151,918,149,7833,090,825,2473,732,518,0005,094,364,0005,324,634,0005,325,336,0005,366,294,0006,265,155,0006,065,734,000
Dividend
Jun 16, 20250.04 HKD/sh
Earnings
Jun 04, 2025

Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
URL
http://www.sinobiopharm.com/
IPO date
Dec 08, 2003
Employees
26,079
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
26,199,409
-8.97%
28,780,412
7.14%
Cost of revenue
20,529,530
22,692,117
Unusual Expense (Income)
NOPBT
5,669,879
6,088,295
NOPBT Margin
21.64%
21.15%
Operating Taxes
797,267
775,986
Tax Rate
14.06%
12.75%
NOPAT
4,872,612
5,312,309
Net income
2,331,939
-53.39%
5,002,618
-65.76%
Dividends
(632,669)
(1,267,622)
Dividend yield
0.98%
1.46%
Proceeds from repurchase of equity
(396,393)
(867,613)
BB yield
0.62%
1.00%
Debt
Debt current
11,207,428
9,723,841
Long-term debt
1,742,698
4,642,816
Deferred revenue
749,070
Other long-term liabilities
1,455,275
131,076
Net debt
(26,349,019)
(19,517,731)
Cash flow
Cash from operating activities
6,065,734
6,265,155
CAPEX
(1,067,823)
(1,705,612)
Cash from investing activities
(756,975)
(4,070,819)
Cash from financing activities
(6,548,990)
(3,186,390)
FCF
7,653,486
4,740,221
Balance
Cash
14,118,175
16,921,663
Long term investments
25,180,970
16,962,725
Excess cash
37,989,175
32,445,367
Stockholders' equity
37,445,183
31,681,310
Invested Capital
14,760,289
20,793,459
ROIC
27.41%
26.28%
ROCE
10.86%
11.42%
EV
Common stock shares outstanding
18,529,065
19,017,202
Price
3.47
-24.07%
4.57
-16.30%
Market cap
64,295,855
-26.02%
86,908,613
-17.45%
EV
45,642,320
85,665,167
EBITDA
6,744,163
7,135,279
EV/EBITDA
6.77
12.01
Interest
495,237
439,058
Interest/NOPBT
8.73%
7.21%